Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Research library
Find psilocybin research topics, selected reports, outcome-measure explanations, primary-source guidance, learning resources and verified conference links.
Free access · No subscription for research tools or data exports
Topics and compounds
Topic labels are derived screening aids; their presence is not a clinical diagnosis or verified study design. Substance filters preserve the distinction between psilocybin and psilocin.
Psilocybin literaturePsilocin literatureDepression · 1784Receptor Pharmacology · 1300Safety · 1251Review Article · 1100Mechanism of Action · 1099Clinical Trial · 1008Anxiety · 905Addiction · 842Pharmacology · 767General · 544Animal Study · 543Aging · 537Observational Study · 534Brain Imaging · 492Treatment-Resistant Depression · 431Emotional Processing · 422Neuroplasticity · 413PTSD · 407Consciousness · 399Toxicity · 387Adverse Events · 353Randomized Controlled Trial · 320Systematic Review · 306Chronic Pain · 301Wellbeing · 285Drug Interactions · 281End-of-Life Distress · 271Spirituality · 271Mystical Experience · 267Healthy Volunteers · 212Biomarkers · 198Microdosing · 192Healthcare Workers · 184Inflammation · 156Headache / Migraine · 153Cancer Patients · 152Personality Change · 150OCD · 149Case Report · 124Meta-Analysis · 124Default Mode Network · 107Eating Disorders · 101In Vitro Study · 85Creativity · 80Adolescents · 75Immune Function · 68Veterans · 50Genomics · 49Psychological Flexibility · 33Epigenetics · 32Older Adults · 32Neurogenesis · 31Resilience · 31Oxidative Stress · 25Transcriptomics · 25Mitochondrial Function · 22Longevity · 20Microbiome · 18Abuse Liability · 16Contraindications · 16Metabolomics · 14Proteomics · 11Cellular Senescence · 6Telomeres · 3Biological Age · 1Inflammaging · 1
Selected reports and research timelines
The evidence guides select randomized primary reports for depression and both controlled and preliminary reports for alcohol use disorder. Selection prioritises an interpretable research question, design and endpoint; it is not a citation-count ranking.
Depression
- Carhart-Harris et al. · 2021 — Primary endpoint not met
- Davis et al. · 2021 — Positive waiting-list comparison
- Goodwin et al. · COMP001 · 2022 — 25 mg primary comparison significant
- Raison et al. · 2023 — Primary endpoint met
- von Rotz et al. · 2023 — Primary outcomes favored psilocybin
- Mertens et al. · EPISODE · 2026 — Primary endpoint not met
- Rucker et al. · NHS feasibility trial · 2026 — Feasibility study
- Yngwe et al. · Stockholm trial · 2026 — Primary endpoint met
Alcohol use disorder
- Bogenschutz et al. · 2015 pilot — Preliminary uncontrolled finding
- Bogenschutz et al. · 2022 — Primary endpoint favored psilocybin
- Swiss relapse-prevention trial · 2025 — Primary comparisons inconclusive
Use the publication timeline layout for citation context and the registry pipeline for study milestones.
Read outcome measures correctly
MADRS
The Montgomery–Åsberg Depression Rating Scale assesses depressive symptom severity. Several selected reports use it, but day 8, week 3 and day 43 endpoints are different assessments. Compare the prespecified time and population, not just the numerical difference.
Reports and original sourcesHAMD and GRID-HAMD
Hamilton depression ratings appear in EPIsoDE and the Davis report. EPIsoDE prespecified a response endpoint; the waiting-list study used a different comparison. A response proportion is not a mean symptom-score difference.
Design and interpretationQIDS-SR
The escitalopram comparison used change in self-reported depression symptoms at week 6 as its primary endpoint. That comparison was not significant. Results from other scales or secondary outcomes do not replace its primary test.
Source-linked comparisonHeavy drinking days and abstinence
The 2022 alcohol trial assessed percentage of heavy drinking days over 32 weeks; the 2025 relapse-prevention report assessed abstinence and consumption after recent withdrawal treatment. These endpoints, populations and treatment programmes differ.
Original reports and correctionThese are reading notes, not reproduced instrument questionnaires or instructions for clinical scoring.
Guidance, training and research centres
Read sources in their original context. Guidance for clinical investigations, professional education and clinical authorisation have different purposes.
Clinical investigation guidance
FDA provides guidance on the design of psychedelic clinical investigations. Check the current document and distinguish regulatory guidance from trial results.
FDA original guidanceJohns Hopkins research and learning
The centre's official site introduces its research and links learning resources, including an introductory online course. Check course availability and terms with the provider.
Official centre and learning resourcesGerman research and exceptional access
ZI Mannheim explains its psilocybin research and programme context. Our country report separates the published evidence from registry and access facts.
Germany report and primary sourcesResearch reading skills
Our guide covers study design, source status, uncertainty and reproducibility. It supports literature appraisal rather than therapist certification.
Free research reading guideExternal resource pages checked 9 October 2026. Source links do not imply affiliation or endorsement.
Verified event sources
Entheo-Science 2027
The organiser announces 11–13 June 2027 in Leipzig. This broader interdisciplinary gathering includes science and other perspectives; the listing is not a claim that every presentation is peer reviewed.
Organiser, programme and updatesICPR
The official conference site says ICPR 2026 has concluded. Follow the organiser for conference resources and any subsequent announcements; no future dates are inferred here.
Official conference siteEvent announcements checked 9 October 2026. Confirm dates and programme changes with the organisers before making plans.